ClinicalTrials.gg
CompletedNCT00447057Updated Oct 13, 2011Results posted

Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Pemetrexed and Erlotinib in Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy., sponsored by Eli Lilly and Company. Completed at 23 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-10-13.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, randomized, Phase 2, open label, parallel trial to evaluate an effect of pemetrexed alone on nonsquamous non-small cell lung cancer (NSCLC) in a second-line setting (such as progression-free survival [PFS], disease control rate, best response rate, time to treatment failure [TTTF], overall survival [OS] and 1-year survival rates) compared to pemetrexed plus erlotinib combination.

02

Conditions studied

  • Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.

Keywords

  • nonsquamous
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of locally advanced or NSCLC that is of nonsquamous histology and not amenable to curative therapy.
  • Failure of previous treatment with one prior platinum-based chemotherapy regimen.
  • Good performance status.
  • Adequate bone marrow reserve, renal and hepatic functions.

Exclusion criteria

Exclusion Criteria:

  • Serious concomitant systemic disease.
  • Inability to take oral medication.
  • Inability or unwillingness to take vitamin supplementation and .
  • Pregnancy / Breast-feeding.
  • Treatment with certain medicines that prevent blood from clotting.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
204 participants (actual)

Study arms

  • Experimental
    Pemetrexed (Nonsquamous)

    Group of participants with non-small cell lung cancer (NSCLC) of nonsquamous histology who were assigned to Pemetrexed arm

    Drug: Pemetrexed

  • Experimental
    Pemetrexed + Erlotinib (Nonsquamous)

    Group of participants with NSCLC of nonsquamous histology who were assigned to Pemetrexed + Erlotinib arm

    Drug: Erlotinib · Drug: Pemetrexed

  • Experimental
    Pemetrexed (Squamous)

    Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed arm

    Drug: Pemetrexed

  • Experimental
    Pemetrexed + Erlotinib (Squamous)

    Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed + Erlotinib arm

    Drug: Pemetrexed · Drug: Erlotinib

Interventions

  • 500 mg/m² intravenous (iv) over 10 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity

    Also known as: LY231514, Alimta

  • 150 mg given orally (po), daily (QD), starting on the first day of the first cycle

    Also known as: Tarceva

  • 500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity

    Also known as: LY231514, Alimta

  • 150 mg given po, QD, starting on the first day of the first cycle

    Also known as: Tarceva

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS per Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 criteria using computed tomography (CT) or magnetic resonance imaging (MRI) for objective determination of progressive disease (PD: ≤20% increase in sum of longest diameter of target lesion). For participants alive as of data cut-off date who did not have PD, PFS was censored at date of last CT/MRI. For participants who received subsequent systemic anticancer therapy (after study discontinuation) prior to PD or death, PFS censored at date of last CT/MRI prior to initiation of post discontinuation systemic anticancer therapy.

    Time frame: Baseline to date of measured PD or death from any cause. Maximum follow-up was from baseline to 32.2 months

Secondary outcomes

  1. Percentage of Participants With Best Response of Stable Disease (SD), Partial Response (PR) or Complete Response (CR) (Disease Control Rate)

    Per RECIST: CR: Disappearance of all target lesions; PR: Either a) ≤30% decrease in sum of longest diameter (LD) of target lesions or b) complete disappearance of target lesions, with persistence (but not worsening) of ≥1 nontarget lesions. In either case, no new lesions may have appeared. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD. PD: ≤20% increase in sum of LD of target lesions. Disease Control Rate (%) = (SD+PR+CR)/number of participants in arm\*100.

    Time frame: Baseline to measured PD. Maximum follow-up was from Baseline to 34 months

  2. Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Response Rate)

    CR: Disappearance of all tumor lesions; PR: Either a) at least a 30% decrease in sum of LD of target lesions or b) complete disappearance of target lesions, with persistence (but not worsening) ≥1 nontarget lesions. In either case, no new lesions may have appeared. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD. PD: ≤20% increase in the sum of LD of target lesions. Response Rate (%) = (CR+PR)/number of participants in arm\*100.

    Time frame: Baseline to measured progressive disease. Maximum follow-up was from Baseline to 34 months

  3. Time to Treatment Failure (TTTF)

    Defined as the time from randomization to death from any cause, first observation of PD, or study treatment discontinuation due to any reason other than "protocol complete" or "satisfactory response". For participants who discontinued due to "protocol complete" or "satisfactory response", or for participants not known to have discontinued as of the data cut-off date, TTTF was censored at the last contact date.

    Time frame: Baseline to first date among death from any cause, PD, or study treatment discontinuation for any reason other than "protocol complete" or "satisfactory response". Maximum follow-up was from Baseline to 32.2 months

  4. Overall Survival (OS)

    OS time is the duration from randomization to the date of death from any cause. For each participant who was not known to have died as of the data inclusion cut-off date, OS was censored at the date of last contact.

    Time frame: Baseline to date of death from any cause. Maximum follow-up was from Baseline to 42.6 months.

  5. Percentage of Participants Surviving at 1 Year

    Overall Survival (OS) rate at 1 year from the date of randomization was determined using the distribution of OS times and was estimated using the Kaplan-Meier method.

    Time frame: Baseline to date of death from any cause up to 1 year

  6. Number of Participants With Adverse Events (AEs)

    Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.

    Time frame: Baseline up to 42.2 months

07

Results

Posted Oct 13, 2011
Limitations and caveats
Baseline Characteristics are presented by histology (nonsquamous/squamous) for each arm. Per the protocol amendment of August 2008, study entry criteria were changed to exclude participants with predominantly squamous cell histology.

Participant flow

Participant flow — Overall Study
MilestonePemetrexed (Nonsquamous)Pemetrexed + Erlotinib (Nonsquamous)Pemetrexed (Squamous)Pemetrexed + Erlotinib (Squamous)
Started83761926
Completed0300
Not completed83731926
Withdrew: Adverse event41003
Withdrew: Death due to study disease6411
Withdrew: Lost to follow-up0100
Withdrew: Entry criteria not met1100
Withdrew: Protocol violation0100
Withdrew: Withdrawal by subject4511
Withdrew: Physician decision9631
Withdrew: Sponsor decision1100
Withdrew: Progressive disease58431318
Withdrew: Death due to adverse event0012
Withdrew: Death, study drug related0100

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS per Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 criteria using computed tomography (CT) or magnetic resonance imaging (MRI) for objective determination of progressive disease (PD: ≤20% increase in sum of longest diameter of target lesion). For participants alive as of data cut-off date who did not have PD, PFS was censored at date of last CT/MRI. For participants who received subsequent systemic anticancer therapy (after study discontinuation) prior to PD or death, PFS censored at date of last CT/MRI prior to initiation of post discontinuation systemic anticancer therapy.

Time frame:
Baseline to date of measured PD or death from any cause. Maximum follow-up was from baseline to 32.2 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsPemetrexed (Nonsquamous)Pemetrexed + Erlotinib (Nonsquamous)
Progression Free Survival (PFS)2.9 (1.94 to 3.38)3.2 (2.86 to 4.70)
Statistical analysis
  • Pemetrexed (Nonsquamous) vs Pemetrexed + Erlotinib (Nonsquamous) · Log Rank · p = 0.0047 · Hazard ratio (hr): 0.63 · 95% CI 0.438 to 0.897Log-rank test with 1-sided alpha of 0.20
SecondaryPercentage of Participants With Best Response of Stable Disease (SD), Partial Response (PR) or Complete Response (CR) (Disease Control Rate)

Per RECIST: CR: Disappearance of all target lesions; PR: Either a) ≤30% decrease in sum of longest diameter (LD) of target lesions or b) complete disappearance of target lesions, with persistence (but not worsening) of ≥1 nontarget lesions. In either case, no new lesions may have appeared. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD. PD: ≤20% increase in sum of LD of target lesions. Disease Control Rate (%) = (SD+PR+CR)/number of participants in arm\*100.

Time frame:
Baseline to measured PD. Maximum follow-up was from Baseline to 34 months
Reported as:
Number · percentage of participants
Percentage of Participants With Best Response of Stable Disease (SD), Partial Response (PR) or Complete Response (CR) (Disease Control Rate)
percentage of participantsPemetrexed (Nonsquamous)Pemetrexed + Erlotinib (Nonsquamous)
Percentage of Participants With Best Response of Stable Disease (SD), Partial Response (PR) or Complete Response (CR) (Disease Control Rate)51.8 (40.6 to 62.9)55.3 (43.4 to 66.7)
Statistical analysis
  • Pemetrexed (Nonsquamous) vs Pemetrexed + Erlotinib (Nonsquamous) · Fisher Exact · p = 0.3909
SecondaryPercentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Response Rate)

CR: Disappearance of all tumor lesions; PR: Either a) at least a 30% decrease in sum of LD of target lesions or b) complete disappearance of target lesions, with persistence (but not worsening) ≥1 nontarget lesions. In either case, no new lesions may have appeared. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD. PD: ≤20% increase in the sum of LD of target lesions. Response Rate (%) = (CR+PR)/number of participants in arm\*100.

Time frame:
Baseline to measured progressive disease. Maximum follow-up was from Baseline to 34 months
Reported as:
Number · percentage of participants
Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Response Rate)
percentage of participantsPemetrexed (Nonsquamous)Pemetrexed + Erlotinib (Nonsquamous)
Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Response Rate)10.8 (5.1 to 19.6)17.1 (9.4 to 27.5)
Statistical analysis
  • Pemetrexed (Nonsquamous) vs Pemetrexed + Erlotinib (Nonsquamous) · Fisher Exact · p = 0.1808
SecondaryTime to Treatment Failure (TTTF)

Defined as the time from randomization to death from any cause, first observation of PD, or study treatment discontinuation due to any reason other than "protocol complete" or "satisfactory response". For participants who discontinued due to "protocol complete" or "satisfactory response", or for participants not known to have discontinued as of the data cut-off date, TTTF was censored at the last contact date.

Time frame:
Baseline to first date among death from any cause, PD, or study treatment discontinuation for any reason other than "protocol complete" or "satisfactory response". Maximum follow-up was from Baseline to 32.2 months
Reported as:
Median · months
Time to Treatment Failure (TTTF)
monthsPemetrexed (Nonsquamous)Pemetrexed + Erlotinib (Nonsquamous)
Time to Treatment Failure (TTTF)2.4 (1.74 to 2.99)3.0 (2.23 to 4.07)
Statistical analysis
  • Pemetrexed (Nonsquamous) vs Pemetrexed + Erlotinib (Nonsquamous) · Log Rank · p = 0.0034 (1-sided significance level of 0.20) · Hazard ratio (hr): 0.64 · 95% CI 0.457 to 0.887
SecondaryOverall Survival (OS)

OS time is the duration from randomization to the date of death from any cause. For each participant who was not known to have died as of the data inclusion cut-off date, OS was censored at the date of last contact.

Time frame:
Baseline to date of death from any cause. Maximum follow-up was from Baseline to 42.6 months.
Reported as:
Median · months
Overall Survival (OS)
monthsPemetrexed (Nonsquamous)Pemetrexed + Erlotinib (Nonsquamous)
Overall Survival (OS)7.8 (5.29 to 10.41)11.8 (8.18 to 16.66)
Statistical analysis
  • Pemetrexed (Nonsquamous) vs Pemetrexed + Erlotinib (Nonsquamous) · Log Rank · p = 0.0190 (1-sided significance level of 0.20) · Hazard ratio (hr): 0.68 · 95% CI 0.465 to 0.981
SecondaryPercentage of Participants Surviving at 1 Year

Overall Survival (OS) rate at 1 year from the date of randomization was determined using the distribution of OS times and was estimated using the Kaplan-Meier method.

Time frame:
Baseline to date of death from any cause up to 1 year
Reported as:
Median · Percentage participants with OS ≥1 year
Percentage of Participants Surviving at 1 Year
Percentage participants with OS ≥1 yearPemetrexed (Nonsquamous)Pemetrexed + Erlotinib (Nonsquamous)
Percentage of Participants Surviving at 1 Year34.1 (23.82 to 44.56)49.4 (37.25 to 60.36)
SecondaryNumber of Participants With Adverse Events (AEs)

Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.

Time frame:
Baseline up to 42.2 months
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsPemetrexed (Nonsquamous and Squamous)Pemetrexed + Erlotinib (Nonsquamous and Squamous)
serious adverse events4353
other adverse events9198

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed (Nonsquamous and Squamous)—43/102 (42.2%)91/102 (89.2%)
Pemetrexed + Erlotinib (Nonsquamous and Squamous)—53/102 (52%)98/102 (96.1%)
Most frequent serious events
Showing 10 of 95
Most frequent serious events
EventPemetrexed (Nonsquamous and Squamous)Pemetrexed + Erlotinib (Nonsquamous and Squamous)
AnaemiaBlood and lymphatic system disorders4/10210/102
Febrile neutropeniaBlood and lymphatic system disorders2/10210/102
General physical health deteriorationGeneral disorders2/1029/102
ThrombocytopeniaBlood and lymphatic system disorders3/1027/102
NeutropeniaBlood and lymphatic system disorders3/1025/102
PneumoniaInfections and infestations3/1024/102
LeukopeniaBlood and lymphatic system disorders1/1023/102
DiarrhoeaGastrointestinal disorders0/1023/102
BronchitisInfections and infestations1/1023/102
Pleural effusionRespiratory, thoracic and mediastinal disorders3/1021/102
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPemetrexed (Nonsquamous and Squamous)Pemetrexed + Erlotinib (Nonsquamous and Squamous)
DiarrhoeaGastrointestinal disorders8/10244/102
RashSkin and subcutaneous tissue disorders9/10243/102
NauseaGastrointestinal disorders24/10232/102
Decreased appetiteMetabolism and nutrition disorders13/10231/102
LeukopeniaBlood and lymphatic system disorders9/10229/102
NeutropeniaBlood and lymphatic system disorders14/10228/102
Weight decreasedInvestigations20/10227/102
AnaemiaBlood and lymphatic system disorders22/10226/102
DyspnoeaRespiratory, thoracic and mediastinal disorders25/10218/102
FatigueGeneral disorders19/10222/102

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed (Nonsquamous)Pemetrexed + Erlotinib (Nonsquamous)Pemetrexed (Squamous)Pemetrexed + Erlotinib (Squamous)Total
Mean59.8 ± 10.2563.5 ± 9.7063.9 ± 9.3366.1 ± 8.5862.3 ± 9.96
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed (Nonsquamous)Pemetrexed + Erlotinib (Nonsquamous)Pemetrexed (Squamous)Pemetrexed + Erlotinib (Squamous)Total
Female34300266
Male49461924138
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pemetrexed (Nonsquamous)Pemetrexed + Erlotinib (Nonsquamous)Pemetrexed (Squamous)Pemetrexed + Erlotinib (Squamous)Total
Caucasian82751926202
African00000
Hispanic10001
Native American00000
East Asian00000
West Asian01001
Region of Enrollment
Region of Enrollment(participants)Pemetrexed (Nonsquamous)Pemetrexed + Erlotinib (Nonsquamous)Pemetrexed (Squamous)Pemetrexed + Erlotinib (Squamous)Total
Austria452011
Germany4437615102
Spain1897741
Hungary12144434
Sweden5110016
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Pemetrexed (Nonsquamous)Pemetrexed + Erlotinib (Nonsquamous)Pemetrexed (Squamous)Pemetrexed + Erlotinib (Squamous)Total
Status 033337982
Status 1393371392
Status 21195429
Unknown01001
Basis for Diagnosis
Basis for Diagnosis(participants)Pemetrexed (Nonsquamous)Pemetrexed + Erlotinib (Nonsquamous)Pemetrexed (Squamous)Pemetrexed + Erlotinib (Squamous)Total
Histopathological64611822165
Cytological19151439
Initial Pathological Diagnosis
Initial Pathological Diagnosis(participants)Pemetrexed (Nonsquamous)Pemetrexed + Erlotinib (Nonsquamous)Pemetrexed (Squamous)Pemetrexed + Erlotinib (Squamous)Total
Adenocarcinoma of the lung706100131
Mixed cell (squamous/adenocarcinoma)11002
Large cell lung carcinoma690015
Bronchioalveolar carcinoma41005
Squamous cell carcinoma of the lung00192645
Unknown24006
Stage of Disease at Study Entry
Stage of Disease at Study Entry(participants)Pemetrexed (Nonsquamous)Pemetrexed + Erlotinib (Nonsquamous)Pemetrexed (Squamous)Pemetrexed + Erlotinib (Squamous)Total
Stage I00000
Stage II00000
Stage IIIA31206
Stage IIIB10114530
Stage IV70641321168

2 further baseline measures are reported on the registry.

08

Study locations

23 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salzburg, 5020, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vienna, A-1140, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bochum, 44791, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Freiburg, 79106, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gauting, 82131, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gerlingen, 70839, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, D 21075, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hannover, 30625, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Immenhausen, 34376, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Trier, 54219, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tübingen, 72076, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ulm, 89075, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Deszk, 6772, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Matrahaza, 3233, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nyiregyhaza, H-4400, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szekesfehervar, 8000, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Alicante, 03010, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08036, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28050, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Valencia, 46010, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Linkoping, 58185, Sweden
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lund, 221 85, Sweden
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Solna, 17176, Sweden
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Jul 2010 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2007
First posted
Mar 13, 2007
Start
Mar 2007
Primary completionActual
Jul 2010
CompletionActual
Jun 2011
Results first posted
Oct 13, 2011
Last update
Oct 13, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00447057
Responsible party
Sponsor
First posted
Mar 13, 2007
Start date
Mar 2007
Primary completion
Jul 2010
Completion
Jun 2011
Results posted
Oct 13, 2011
Last update
Oct 13, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion